InMed Pharmaceuticals Inc.

INM • Drug Manufacturers - Specialty & Generic

$1.36

— 0.00 (0.00%)

EarningsLatest report: Jun 30, 2026

WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.

Market Cap

$5.95M

Growth

33.1%

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 1.37Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Sep 25, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.36

Change0.00%

Shares Out4.37M

Market Cap$5.95M

Enterprise Value$3.72M

52W Range0.57 - 2.50

Beta0.98

P/E-0.47

P/S0.00

P/B5.53

P/FCF-0.59

EV/Sales0.00

Price$1.36

Change0.00%

Shares Out4.37M

Market Cap$5.95M

Enterprise Value$3.72M

52W Range0.57 - 2.50

Beta0.98

P/E-0.47

P/S0.00

P/B5.53

P/FCF-0.59

EV/Sales0.00

EV/EBITDA-0.38

EV/FCF-0.37

Earnings Yield-211.19%

FCF Yield-170.44%

Dividend Yield0.00%

Gross Margin22.35%

Oper. Margin-0.31%

Profit Margin-0.40%

Debt/Eq0.00

Current Ratio1.37

Quick Ratio1.37

Revenue 5Y33.12%

Volume38.96K

Avg Volume2.54M

EPS Surprise93.75

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

60/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

74/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 1.37Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

INM

Analyst sentiment

Based on 2 analyst votes · 2026-10-20

100/100

Bullish

Hold

Bearish

Company Overview

IPO: 5/5/2014

Industry: Drug Manufacturers - Specialty & Generic

P/B i: 5.53

Debt / Equity i: 0.00

Operating Margin: -0.31%

Net Margin: -0.40%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 0.00

Current Ratio: 1.37

Quick Ratio: 1.37

Status: Good

Insider Transactions

Recent executive and insider activity

ADAR1 Capital Management, LLC

Transaction: 09/16/2026

BUY

Change

+8,340

Price

$1.29

Filing

09/16/2026

Type

BUY

ADAR1 Capital Management, LLC

Transaction: 09/15/2026

BUY

Change

+54,256

Price

$1.30

Filing

09/16/2026

Type

BUY

ADAR1 Capital Management, LLC

Transaction: 09/14/2026

BUY

Change

+28,505

Price

$1.29

Filing

09/16/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
ADAR1 Capital Management, LLC	BUY	+8,340	$1.29	09/16/2026	09/16/2026
ADAR1 Capital Management, LLC	BUY	+54,256	$1.30	09/15/2026	09/16/2026
ADAR1 Capital Management, LLC	BUY	+28,505	$1.29	09/14/2026	09/16/2026
ADAR1 Capital Management, LLC	BUY	+1,000	$1.55	07/15/2026	07/17/2026
Vivo Opportunity, LLC	BUY	+2	$1.55	07/16/2026	07/16/2026
Vivo Opportunity, LLC	BUY	+1,389	$1.55	07/15/2026	07/16/2026
Vivo Opportunity, LLC	BUY	+493	$1.55	07/14/2026	07/16/2026
Vivo Opportunity, LLC	BUY	+147	$1.55	07/02/2026	07/02/2026
Vivo Opportunity, LLC	BUY	+398	$1.55	07/01/2026	07/02/2026
Vivo Opportunity, LLC	BUY	+55	$1.54	06/30/2026	07/02/2026
Vivo Opportunity, LLC	BUY	+2,982	$1.52	06/08/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+5,045	$1.57	06/05/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+618	$1.57	06/04/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+714	$1.55	06/03/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+2,095	$1.52	06/02/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+1,498	$1.55	06/01/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+1,632	$1.57	05/29/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+3,118	$1.69	05/21/2026	06/10/2026
Vivo Opportunity, LLC	BUY	+5,154	$1.56	05/20/2026	06/10/2026
Vivo Opportunity, LLC	OTHER	0	Not reported	05/19/2026	06/10/2026

About the Company

InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

Source - link

Peers

BDRX BIVI CNSP ESLA GLMD GNPX GRI JAGX KZIA SILO

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

InMed Pharmaceuticals Inc. (NASDAQ:INM) Shares Shorted: Short Interest Down 48.4% in September

InMed Pharmaceuticals Inc. (NASDAQ: INM - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 15,876 shares, a decline of 48.4% from the August 31st total of 30,769 shares. Approximately 0.5% of the company's shares are short sold.

Defense World

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2026, was below the minimum shareholders' equity of $2,500,000 required for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1). The decline in the Company's shareholders' equity is attributable largely to transaction-related expenses accrued in connection with the Company's previously announced Agreement and Plan of Merger and Reorganization dated May 19, 2026 (as amended, the "Merger Agreement") entered into with Mentari Therapeutics, Inc. ("Mentari"), pursuant to which, among other things, the Company will merge with Mentari (the "Merger").

Newsfile Corp

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026. The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.

Newsfile Corp

Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)

InMed Pharmaceuticals (NASDAQ: INM - Get Free Report) and Reviva Pharmaceuticals (NASDAQ: RVPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation. Institutional and Insider Ownership 20.1% of InMed

Defense World

InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline

Mentari Therapeutics, a privately held biotechnology enterprise dedicated to preventing migraines, has successfully secured an additional $200 million through a new private placement.

Benzinga

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-06	-94.44358	-0.69	93.75358
2023-09-29	-85	-12.92	72.08
2023-05-15	-90	-12	78
2023-02-17	-90	-18.2	71.8
2022-11-11	-85	-81.2	3.8
2022-09-23	-110	-258.4	-148.4
2022-05-13	-115	-125	-10
2022-02-14	-120	-155	-35
2021-11-10	-175	-125	50
2021-09-24	-170	-205	-35
2021-05-13	-120	-205	-85
2021-02-11	-120	-185	-65